POZ Community Forums
Meds, Mind, Body & Benefits => Research News & Studies => Topic started by: Delby on September 20, 2012, 04:50:25 am
-
Summary from the 19th IAC 2012 in Washington DC.
There seems to be a couple of drugs in the pipeline, mainly S/GSK1265744 (744) by ViiV & GSK, an agent that can be considered for delivery as an injectable antiretroviral which could be delivered as infrequently as once per month or perhaps longer.
http://www.natap.org/2012/IAS/IAS_105.htm
Thoughts?
Delby 8)
-
Nice read.
Dolutegravir also seems very exciting, ,maybe even more than 744 me thinks, I dont mind the pills every day but more long term toxicity.
If it is as good as the author states in terms of side effects and viral suppression it would be a very good addition to the arsenal of ARVs, I almost even get the feeling its too good to be true!
A thought about this paper and looking at the development.
Why are there so few new NRTIs?
If Im not mistaken Emtracitabine was the last one in 2003, thats almost 10 years ago,NRTIs being the backbone to most regimens I cant understand this.
During these years there have been new drugs in all other categories.
-
Dolutegravir also seems very exciting,
My doctor, who is also an hiv pharmacologist, is VERY excited about this new med. He says it's the best one to come along in a long time.
-
I just did blood work last week to start participating in this trial mentioned in your link:
We'll see how it goes :)
Summary from the 19th IAC 2012 in Washington DC.
There seems to be a couple of drugs in the pipeline, mainly S/GSK1265744 (744) by ViiV & GSK, an agent that can be considered for delivery as an injectable antiretroviral which could be delivered as infrequently as once per month or perhaps longer.
-
goodluck Lincoln6echo and thank you! :D please keep us all updated
-
Thanks Gio! and yeah, I will let you know how it goes :)
-
Thanks Gio! and yeah, I will let you know how it goes :)
Hi Lincoln,
Good luck with the trial and I hope it goes well for you. Keep us updated. So what do you have to do for the trial? Assuming it's for the S/GSK1265744 (744)?
Delby :)
-
Hey Delby
Thanks for your note ;)
Yep, that's the one, 744.
I'll find out on Monday if I'm good to go for the trial (doc said the only reason in my case at this point I wouldn't be is if I had a resistant strain to the meds from the trial).
I'll be on one of four options - the new drug at one of three doses 10, 30 or 60 mg plus two already existing drugs and a placebo, or i'll be part of the control group taking already available drugs at standard doses.
The Induction Phase consists of a 24 week dose-ranging evaluation of GSK1265744 at blinded doses of 10 mg, 30 mg and 60 mg once-daily and a control arm of open-label efavirenz (EFV) 600 mg once daily. The background dual nucleoside reverse transcriptase inhibitor (NRTI) antiretroviral therapy (ART) for all arms will be either abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC) as selected by the Investigator.
for the first month it's a once a week visit to the clinic with blood tests and ECG plus every time you go in you do an automated phone interview assessing your suicide risk.
after the first month the visits become less frequent.
should be interesting...